|
US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
|
ES2249838T3
(es)
*
|
1997-07-11 |
2006-04-01 |
The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services |
Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
|
|
US6809184B1
(en)
*
|
1997-12-01 |
2004-10-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
|
DE60028361T2
(de)
*
|
1999-02-26 |
2007-05-10 |
Pacific Northwest Research Institute, Seattle |
Verfahren und zusammensetzungen zur karzinomdiagnose
|
|
US6770445B1
(en)
*
|
1999-02-26 |
2004-08-03 |
Pacific Northwest Research Institute |
Methods and compositions for diagnosing carcinomas
|
|
US7745159B2
(en)
|
1999-02-26 |
2010-06-29 |
Nathalie B Scholler |
Methods and compositions for diagnosing carcinomas
|
|
ATE401348T1
(de)
|
1999-05-27 |
2008-08-15 |
Us Gov Health & Human Serv |
Immunokonjugate mit hoher bindungsaffinität
|
|
GB9924351D0
(en)
|
1999-10-14 |
1999-12-15 |
Brennan Frank |
Immunomodulation methods and compositions
|
|
US6987024B1
(en)
*
|
2000-04-10 |
2006-01-17 |
Raven Biotechnologies, Inc. |
Human ovarian mesothelial cells and methods of isolation and uses thereof
|
|
AU2002338446A1
(en)
*
|
2001-01-23 |
2002-11-05 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
|
EP2371854B1
(en)
*
|
2001-03-09 |
2014-05-07 |
Board Of Regents, The University Of Texas System |
Induction of tumor immunity by variants of folate binding protein
|
|
WO2004006837A2
(en)
*
|
2002-07-12 |
2004-01-22 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
|
US20090110702A1
(en)
*
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
|
WO2004084936A2
(en)
*
|
2003-02-06 |
2004-10-07 |
Cerus Corporation |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
JP4545151B2
(ja)
*
|
2003-02-06 |
2010-09-15 |
シーラス コーポレイション |
非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
|
|
US7695725B2
(en)
*
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
US20040180387A1
(en)
*
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
|
EP1651675A1
(en)
*
|
2003-08-05 |
2006-05-03 |
Morphotek, Inc. |
A variant cell surface molecule associated with cancer
|
|
US7399793B2
(en)
*
|
2003-10-31 |
2008-07-15 |
Basf Corporation |
Coating composition curable with ultraviolet radiation
|
|
CN107213469A
(zh)
*
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
US7842289B2
(en)
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
|
US20060014221A1
(en)
*
|
2004-01-21 |
2006-01-19 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
|
|
EP2444805A3
(en)
|
2004-01-21 |
2012-06-20 |
Fujirebio America, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
|
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
EP1861425B1
(en)
|
2005-03-10 |
2012-05-16 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
AU2006241099B2
(en)
|
2005-04-22 |
2012-04-19 |
Eisai, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
|
US7935804B2
(en)
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
|
JP5347135B2
(ja)
|
2006-03-01 |
2013-11-20 |
アドゥロ バイオテック |
遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
|
|
US20090047673A1
(en)
*
|
2006-08-22 |
2009-02-19 |
Cary Robert B |
Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
|
|
JP2010524508A
(ja)
*
|
2007-04-27 |
2010-07-22 |
ダウ グローバル テクノロジーズ インコーポレイティド |
可溶性組換え二十面体ウイルス様粒子の生産及びインビボ組織化の改善
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
JP2009028871A
(ja)
|
2007-07-30 |
2009-02-12 |
Denso Wave Inc |
ロボット制御装置
|
|
CA2700860C
(en)
|
2007-10-01 |
2016-07-19 |
Jonathan A. Terrett |
Human antibodies that bind mesothelin, and uses thereof
|
|
CN104151429B
(zh)
*
|
2007-11-26 |
2018-07-10 |
拜耳知识产权有限责任公司 |
抗-间皮素抗体及其用途
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
EP2257572A1
(en)
*
|
2008-03-27 |
2010-12-08 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Human anti-mesothelin monoclonal antibodies
|
|
US8785134B2
(en)
*
|
2008-11-10 |
2014-07-22 |
The Mitre Corporation |
Glycoprotein vesicles and their methods of use
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
EP2475398B1
(en)
|
2009-09-11 |
2015-05-20 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
|
US8734798B2
(en)
*
|
2009-10-27 |
2014-05-27 |
Ucb Pharma S.A. |
Function modifying NAv 1.7 antibodies
|
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
JP5879667B2
(ja)
|
2011-04-20 |
2016-03-08 |
メサ バイオテック，インク． |
核酸の検出および同定のための一体型デバイス
|
|
BR112013028537A2
(pt)
|
2011-05-06 |
2017-01-17 |
Us Gov Health & Human Serv |
imunotoxina recombinante que visa a mesotelina
|
|
AR087380A1
(es)
*
|
2011-07-27 |
2014-03-19 |
Baylor Res Inst |
Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
|
|
US9127081B2
(en)
|
2012-05-10 |
2015-09-08 |
Washington University |
Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP2888282B1
(en)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
JP6307085B2
(ja)
|
2012-09-27 |
2018-04-04 |
ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ |
メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
|
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016172724A1
(en)
|
2015-04-24 |
2016-10-27 |
Mesa Biotech, Inc. |
Fluidic test cassette
|
|
WO2016196506A1
(en)
|
2015-05-29 |
2016-12-08 |
Galena Biopharma, Inc. |
PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
EP3733201A1
(en)
|
2016-01-19 |
2020-11-04 |
Pfizer Inc |
Cancer vaccines
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
EP3463438B1
(en)
|
2016-05-31 |
2022-04-06 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Vaccine therapy for treatment of endometrial and ovarian cancer
|
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
EP3707160A1
(en)
|
2017-11-10 |
2020-09-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting tumor antigens
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
EP3883608A1
(en)
|
2019-01-08 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025240496A1
(en)
|
2024-05-14 |
2025-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
|